Compare DBL & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DBL | XOMA |
|---|---|---|
| Founded | 2011 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.6M | 308.6M |
| IPO Year | N/A | N/A |
| Metric | DBL | XOMA |
|---|---|---|
| Price | $14.62 | $26.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | 72.1K | ★ 118.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $76.93 |
| Revenue Next Year | N/A | $29.28 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.46 | $18.40 |
| 52 Week High | $16.01 | $39.92 |
| Indicator | DBL | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 32.05 | 50.33 |
| Support Level | N/A | $23.92 |
| Resistance Level | $15.56 | $27.61 |
| Average True Range (ATR) | 0.09 | 1.47 |
| MACD | -0.03 | 0.12 |
| Stochastic Oscillator | 26.26 | 47.54 |
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.